A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus (Synergy)

  • End date
    Jan 24, 2024
  • participants needed
  • sponsor
    Alpine Immune Sciences, Inc.
Updated on 24 October 2022
human papilloma virus vaccine


This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 in adults with moderate to severe active systemic lupus erythematosus (SLE)

Condition Systemic Lupus Erythematosus
Treatment Placebo, ALPN-101
Clinical Study IdentifierNCT04835441
SponsorAlpine Immune Sciences, Inc.
Last Modified on24 October 2022


Yes No Not Sure

Inclusion Criteria

Written informed consent
Age 18 to 65
Diagnosis of lupus for ≥ 6 months prior to Screening
Positive ANA and/or elevated anti-dsDNA and/or elevated anti-Smith antibody test at Screening
Active lupus at Screening and Baseline, as defined per-protocol and confirmed by the study's medical monitor, including a SLEDAI score at Screening of ≥ 6 and a clinical score at Baseline of ≥ 4
Standard lupus medications must be stable prior to Screening
Women must have a PAP smear and known HPV status within 12 months of Day 1
All participants must use highly effective birth control if they/their partner are capable of becoming pregnant

Exclusion Criteria

Life-threatening or organ system-threatening lupus activity that is anticipated to require increased treatment during the study
Proteinuria consistent with nephrotic syndrome
Active lupus-related neuropsychiatric disease
Drug-induced lupus
Any serious health condition that would place the subject at undue risk from the study or would confound interpretation of safety or efficacy outcomes
Recent or serious ongoing infection; risk or history of serious infection
Receipt of live vaccination within 8 weeks of Day 1, or expected to require live vaccination during the study
Unacceptable Screening laboratory results
History of new, ongoing, or recurrent malignancy ≤ 5 years prior to Day 1, with some exceptions per-protocol
Pregnant or breastfeeding at the time of screening, or plans to become pregnant ≤ 3 months following the last dose of study drug
Prior diagnosis of, or fulfills diagnostic criteria for, another rheumatic disease that overlaps with lupus or another autoimmune or inflammatory disease that may confound clinical assessments or increase subject risk in the study
Diagnosis of, or fulfills diagnostic criteria for, fibromyalgia
Functional class IV lupus
Does not meet protocol washout periods for concomitant medications
Serious lupus disease activity, which warrants immediate immunosuppressive therapy not appropriate for the study or which makes the possibility of receiving placebo or investigational agent an inappropriate risk
Ongoing participation in another therapeutic clinical trial
Known hypersensitivity to ALPN-101, components thereof, or excipients contained in the drug formulation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note